Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PALO ALTO, CALIF., SEPT. 10, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (BRIDGEBIO OR THE COMPANY), A NEW TYPE OF BIOPHARMACEUTICAL COMPANY FOCUSED ON GENETIC DISEASES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF ITS BOARD OF DIRECTORS (THE COMMITTEE) APPROVED EQUITY GRANTS IN THE FORM OF RESTRICTED STOCK UNITS (RSUS) TO NEW EMPLOYEES UNDER THE COMPANY'S AMENDED AND RESTATED 2019 INDUCEMENT EQUITY PLAN (THE PLAN). THE COMMITTEE APPROVED: (I) ON SEPTEMBER 5, 2025, RSU GRANTS COVERING AN AGGREGATE OF 33,684 SHARES OF THE COMPANY'S COMMON STOCK TO 13 NEW EMPLOYEES; (II) ON AUGUST 4, 2025, RSU GRANTS COVERING AN AGGREGATE OF 32,145 SHARES OF THE COMPANY'S COMMON STOCK TO 16 NEW EMPLOYEES; AND (III) ON JULY 14, 2025, RSU GRANTS COVERING AN AGGREGATE OF 73,991 SHARES OF THE COMPANY'S COMMON STOCK TO 20 NEW EMPLOYEES. ONE-FOURTH OF THE SHARES UNDERLYING THESE RSUS WILL VEST ON AUGUST 16, 2026, WITH THE REMAINING SHARES VESTING IN EQUAL QUARTERLY INSTALLMENTS OVER THE FOLLOWING THREE YEARS, SUBJECT TO CONTINUED EMPLOYMENT WITH BRIDGEBIO OR ITS SUBSIDIARIES ON EACH APPLICABLE VESTING DATE. SEPARATELY, ON JUNE 6, 2025, THE COMMITTEE APPROVED RSU GRANTS COVERING AN AGGREGATE OF 98,348 SHARES OF THE COMPANY'S COMMON STOCK TO 25 NEW EMPLOYEES, WITH ONE-FOURTH OF THE SHARES VESTING ON MAY 16, 2026, AND THE BALANCE VESTING IN EQUAL QUARTERLY INSTALLMENTS OVER THE FOLLOWING THREE YEARS, ALSO SUBJECT TO CONTINUED EMPLOYMENT WITH BRIDGEBIO OR ITS SUBSIDIARIES ON EACH APPLICABLE VESTING DATE.

BRIDGEBIO PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

- 80% OF POST-SURGICAL HYPOPARATHYROIDISM PARTICIPANTS ACHIEVED CONCOMITANT BLOOD AND 24-HOUR URINE CALCIUM IN THE NORMAL REFERENCE RANGE WITHIN 5 DAYS OF ENCALERET TREATMENT INITIATION COMPARED TO 0% OF PARTICIPANTS ON CONVENTIONAL THERAPY AT BASELINE

ENCALERET SHOWED PARATHYROID HORMONE-INDEPENDENT NORMALIZATION OF BLOOD AND URINE CALCIUM IN PHASE 2 PROOF-OF-CONCEPT STUDY IN POST-SURGICAL HYPOPARATHYROIDISM

PALO ALTO, CALIF., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (BRIDGEBIO OR THE COMPANY), A NEW TYPE OF BIOPHARMACEUTICAL COMPANY FOCUSED ON GENETIC DISEASES, TODAY ANNOUNCED THE COMPANY WILL HOST AN INVESTOR WEBINAR ON WEDNESDAY, SEPTEMBER 10, 2025 AT 8:00 AM ET WITH RACHEL GAFNI, M.D., SENIOR RESEARCH PHYSICIAN AT THE NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH, PART OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND PRINCIPAL INVESTIGATOR AND STEERING COMMITTEE CO-CHAIR FOR CALIBRATE, THE COMPANY'S PHASE 3 CLINICAL TRIAL FOR AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1).

BRIDGEBIO TO HOST AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) INVESTOR WEBINAR ON WEDNESDAY, SEPTEMBER 10TH AT 8:00 AM ET

PALO ALTO, CALIF., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (BRIDGEBIO OR THE COMPANY), A NEW TYPE OF BIOPHARMACEUTICAL COMPANY FOCUSED ON GENETIC DISEASES, ANNOUNCED TODAY THAT AN ORAL PRESENTATION OF PHASE 2 DATA IN POST-SURGICAL HYPOPARATHYROIDISM AND TWO POSTER SESSIONS ON SKELETAL DYSPLASIA DATA WILL BE SHARED AT THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH (ASBMR) ANNUAL MEETING 2025, TAKING PLACE IN SEATTLE, WA FROM SEPTEMBER 5 - 8, 2025.

BRIDGEBIO TO PRESENT PHASE 2 PROOF-OF-CONCEPT DATA FOR ENCALERET IN POST-SURGICAL HYPOPARATHYROIDISM

- ACORAMIDIS DEMONSTRATED A SIGNIFICANT REDUCTION IN RISK OF CVM THROUGH 42 MONTHS POST-RANDOMIZATION, WITH A 44% HAZARD REDUCTION, SETTING A NEW STANDARD FOR CVM OUTCOMES FOR PATIENTS WITH ATTR-CM

ACORAMIDIS DEMONSTRATES STATISTICALLY SIGNIFICANT REDUCTION IN CARDIOVASCULAR MORTALITY (CVM) THROUGH MONTH 42 OF THE ATTRIBUTE-CM OPEN LABEL EXTENSION

PALO ALTO, CALIF., AUG. 25, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (BRIDGEBIO OR THE COMPANY), A NEW TYPE OF BIOPHARMACEUTICAL COMPANY FOCUSED ON GENETIC DISEASES, ANNOUNCED TODAY THAT ONE RAPID-FIRE ORAL PRESENTATION ON ADDITIONAL OPEN-LABEL EXTENSION DATA FROM ATTRIBUTE-CM AND TWO EPOSTERS WITH ATTRIBUTE-CM DATA AT MONTH 30 WILL BE SHARED AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2025, TAKING PLACE IN MADRID, SPAIN FROM AUGUST 29 - SEPTEMBER 1, 2025.

BRIDGEBIO TO PRESENT ADDITIONAL OPEN-LABEL EXTENSION DATA FROM ATTRIBUTE-CM AT ESC CONGRESS 2025

- AS OF AUGUST 1, 2025, 3,751 UNIQUE PATIENT PRESCRIPTIONS HAVE BEEN WRITTEN BY 1,074 UNIQUE PRESCRIBERS, REPRESENTING AN ACCELERATING LAUNCH DRIVEN BY STRONG MONTH OVER MONTH GROWTH IN THE CRUCIAL TREATMENT NAVE PATIENT SEGMENT

BRIDGEBIO REPORTS SECOND QUARTER 2025FINANCIAL RESULTS AND BUSINESS UPDATES

- BY EXAMINING OVER 100 UNIQUE VARIANTS ASSOCIATED WITH THE CASR GENE CAUSATIVE OF ADH1, THE AVERAGE FREQUENCY OF GAIN-OF-FUNCTION CASR VARIANTS WAS ~3.7 PER 100,000, CLOSELY ALIGNED TO PREVIOUSLY PUBLISHED ESTIMATES 1 (3.9 PER 100,000), WHICH EQUATES TO APPROXIMATELY 25,000 CARRIERS OF ADH1-CAUSING VARIANTS IN THE US AND EU

NOVEL HUMAN GENETICS EVIDENCE CONFIRMS ESTIMATES OF GENETIC PREVALENCE, UNDERDIAGNOSIS, AND POTENTIALLY GREATER SYMPTOM BURDEN OF GAIN-OF-FUNCTION CASR VARIANTS ASSOCIATED WITH ADH1

PALO ALTO, CALIF., JULY 22, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (BRIDGEBIO OR THE COMPANY), A NEW TYPE OF BIOPHARMACEUTICAL COMPANY FOCUSED ON GENETIC DISEASES, TODAY ANNOUNCED THAT IT WILL RELEASE ITS SECOND QUARTER FINANCIAL RESULTS AND BUSINESS UPDATES AFTER THE MARKET CLOSES ON TUESDAY, AUGUST 5, 2025. BRIDGEBIO WILL HOST A CONFERENCE CALL TO DISCUSS THE FINANCIAL RESULTS AND PROGRAM UPDATES AT 4:30 PM ET THE SAME DAY.

BRIDGEBIO TO HOST SECOND QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL ON TUESDAY, AUGUST 5, 2025 AT 4:30 PM ET

PALO ALTO, CALIF., JUNE 30, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (BRIDGEBIO OR THE COMPANY), A NEW TYPE OF BIOPHARMACEUTICAL COMPANY FOCUSED ON GENETIC DISEASES, TODAY ANNOUNCED IT HAS SOLD A PORTION OF ROYALTIES DUE TO THE COMPANY FROM SALES OF BEYONTTRA IN EUROPE TO HEALTHCARE ROYALTY (HCRX) AND FUNDS MANAGED BY BLUE OWL CAPITAL (BLUE OWL) FOR $300 MILLION. THIS ROYALTY FINANCING AGREEMENT MONETIZES SELECT ANTICIPATED ROYALTIES AND PROVIDES IMMEDIATE LESS-DILUTIVE CAPITAL TO THE COMPANY.

BRIDGEBIO RAISES $300 MILLION THROUGH PARTIAL CAPPED MONETIZATION OF BEYONTTRA EUROPEAN ROYALTY

PALO ALTO, CALIF., JUNE 26, 2025 (GLOBE NEWSWIRE) -- BRIDGEBIO PHARMA, INC. (NASDAQ: BBIO) (BRIDGEBIO OR THE COMPANY), A NEW TYPE OF BIOPHARMACEUTICAL COMPANY FOCUSED ON GENETIC DISEASES, TODAY ANNOUNCED THE COMPANY WILL HOST AN INVESTOR WEBINAR ON FRIDAY, JULY 11, 2025 AT 8:00 AM ET WITH MATTHEW WICKLUND, M.D., FAAN, PROFESSOR OF NEUROLOGY AND VICE CHAIR FOR RESEARCH, DEPARTMENT OF NEUROLOGY AT THE UNIVERSITY OF TEXAS (UT) HEALTH SCIENCE CENTER SAN ANTONIO.

BridgeBio Pharma, Inc.

BBIO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BridgeBio Pharma, Inc.

BBIO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BBIO